Keyword: Imfinzi (durvalumab)
Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.
Here’s a familiar sentence: A combo of Imfinzi and tremelimumab missed its primary endpoint. This time, it applies to a small-cell lung cancer trial.
Imfinzi, given alone or in tandem with AZ's troubled CTLA4 tremelimumab, failed against chemo in first-line bladder cancer.
Because of the China COVID-19 epidemic, AstraZeneca pared its 2020 revenue forecast—and at a time when three key cancer meds missed their marks.
While a Keytruda-chemo combo showed significant improvement in cutting disease worsening or death in SCLC, it didn't extend patients' lives.
Lately, pharmas have been rebranding—more often than not, around oncology, rare diseases or both—and more could join the fold in 2020.
AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.
With the priority review, Imfinzi is now looking at a decision for use in frontline small cell lung cancer by the first quarter of 2020.
Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.